On Tuesday, 10x Genomics Inc (NASDAQ: TXG) was 0.93% up from the session before settling in for the closing price of $10.79. A 52-week range for TXG has been $6.78 – $24.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -36.10% over the past five years. When this article was written, the company’s average yearly earnings per share was at 20.25%. With a float of $105.63 million, this company’s outstanding shares have now reached $109.08 million.
Let’s look at the performance matrix of the company that is accounted for 1306 employees. In terms of profitability, gross margin is 68.79%, operating margin of -27.6%, and the pretax margin is -24.56%.
10x Genomics Inc (TXG) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 10x Genomics Inc stocks. The insider ownership of 10x Genomics Inc is 15.39%, while institutional ownership is 90.00%. The most recent insider transaction that took place on May 22 ’25, was worth 77,540. In this transaction Chief Executive Officer of this company sold 9,343 shares at a rate of $8.30, taking the stock ownership to the 1,083,625 shares. Before that another transaction happened on May 22 ’25, when Company’s insider sold 7,485 for $8.30, making the entire transaction worth $62,120. This insider now owns 448,374 shares in total.
10x Genomics Inc (TXG) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.87% during the next five years compared to -36.10% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
You can see what 10x Genomics Inc (TXG) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.18. Likewise, its price to free cash flow for the trailing twelve months is 29.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.30, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
10x Genomics Inc (NASDAQ: TXG) saw its 5-day average volume 3.28 million, a negative change from its year-to-date volume of 3.33 million. As of the previous 9 days, the stock’s Stochastic %D was 71.60%.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 46.60%, which indicates a significant decrease from 87.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.01% in the past 14 days, which was lower than the 77.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.09, while its 200-day Moving Average is $13.43. Nevertheless, the first resistance level for the watch stands at $11.11 in the near term. At $11.32, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.49. If the price goes on to break the first support level at $10.72, it is likely to go to the next support level at $10.55. Assuming the price breaks the second support level, the third support level stands at $10.34.
10x Genomics Inc (NASDAQ: TXG) Key Stats
There are 123,134K outstanding shares of the company, which has a market capitalization of 1.36 billion. As of now, sales total 610,790 K while income totals -182,630 K. Its latest quarter income was 154,880 K while its last quarter net income were -34,360 K.
